Clinical trial / 2005
Formula with DHA and arachidonic acid showed possible neurodevelopmental benefits in larger preterm infants.
In a double-blind randomized comparative study, 27 preterm infants received formula with (n=16) or without (n=11) arachidonic acid (AA) and docosahexaenoic acid (DHA) for 6 months. Mean Mental Development Index scores for supplemented versus non-supplemented groups were 96.1 +/- 8.6 vs 91.7 +/- 10.4 at 6 months and 98.7 +/- 8.0 vs 90.5 +/- 6.9 at 1 year (p = 0.020). Mean Physical Development Index scores were 102.2 +/- 10.5 vs 95.4 +/- 13.2 at 6 months and 98.0 +/- 5.8 vs 86.7 +/- 11.1 at 1 year (p = 0.008). No differences were found in visual acuity, physical examination variables, or vital signs, and no obvious adverse effects occurred.
- Study type
- Double-blind randomized comparative trial
- Who was studied
- 27 preterm infants (gestational age 30 to 37 weeks, birth weight over 2000 g)
- What was measured
- Cognitive development, visual acuity, physical examinations, vital signs, adverse events
THE PAPER
The effect of supplementation of docosahexaenoic acid and arachidonic acid on visual acuity and neurodevelopment in larger preterm infants.
Fang PC, Kuo HK, Huang CB, Ko TY, Chen CC, Chung MY. Chang Gung Med J, 2005.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.